Among the overweight subjects in this study, we observed no significant associations between the effects of the PNPLA3 genotype and the risk of NAFLD and/or a decline in eGFR (Tables 2 and 3). The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.